Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel DiseaseECCO '16 Amsterdam
Year: 2016
Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, T. Kallemose3, G. Houen4, L.B. Riis5, P. S. Munkholm6, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, 4Statens Serum Institute, Department of Autoimmunology and Biomarkers, Copenhagen, Denmark, 5Herlev Hospital, Department of Pathology, Herlev, Denmark, 6North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohn’s disease: a multicentre cohort studyECCO '16 Amsterdam
Year: 2016
Authors:

H. Tanaka*1, N. Kamata2, A. Yamada3, K. Endo4, T. Fujii5, T. Yoshino6, 7, T. Sugaya8, Y. Yokoyama9, S. Bamba10, J. Umeno11, Y. Yanai12, M. Ishii13, T. Kawaguchi14, S. Shinzaki15, Y. Toya16, T. Kobayashi17, M. Nojima18, T. Hibi17

1Sapporo Kosei General Hospital, IBD Centre, Sapporo, Japan, 2Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 3Sakura Medical Centre, Toho University, Department of Internal Medicine, Chiba, Japan, 4Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 7Tazuke Kofukai Medical Research Institute, Kitano Hospital, IBD Centre, Osaka, Japan, 8Dokkyo Medical University, Department of Gastroenterology, Tochigi, Japan, 9Hyogo College of Medicine, Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, 10Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan, 11Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 12Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 13Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan, 14Tokyo Yamate Medical Centre, Department of Internal Medicine, Division of IBD, Tokyo, Japan, 15Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan, 16School of Medicine, Iwate Medial University, Division of Gastroenterology, Iwate, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan, 18The Institute of Medical Science, The University of Tokyo, Centre for Translational Research, Tokyo, Japan

DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease—results at year 7ECCO '16 Amsterdam
Year: 2016
Authors:

G. D’Haens1, W. Reinisch*2, J. Satsangi3, E. Loftus Jr4, R. Panaccione5, H. Read6, M. Heinrich7, J. Petersson6, A.M. Robinson6

1Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 4Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AbbVie Inc., North Chicago, Illinois, United States, 7AbbVie Deutschland, Ludwigshafen, Germany

DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programmeECCO '16 Amsterdam
Year: 2016
Authors:

J.-F. Colombel*1, W. Reinisch2, P. Gibson3, W. J. Sandborn4, B. Feagan5, S. Xu6, R. Strauss6, H. Zhang6, D. Tarabar7, Z. Hebzda8, P. Rutgeerts9, C. Marano6

1Mount Sinai, Icahn School of Medicine, New York, New York, United States, 2Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, 3Alfred Hospital, Melbourne, Australia, 4University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 5Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 6Janssen R & D, LLC, Spring House, Pennsylvania, United States, 7Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia, 8Military Hospital, Krakow, Poland, 9University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands

DOP049: Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS studyECCO '16 Amsterdam
Year: 2016
Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

1University of Liverpool, Liverpool, United Kingdom, 2Glasgow Royal Infirmary, Glasgow, United Kingdom, 3Leeds Teaching Hospitals Trust, Leeds, United Kingdom, 4Guy’s and St. Thomas’ Hospitals, London, United Kingdom, 5Hull & East Yorkshire NHS Trust, Hull, United Kingdom, 6MSD UK, Hoddesdon, United Kingdom

DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studiesECCO '16 Amsterdam
Year: 2016
Authors:

G. D’Haens1, J.-F. Colombel*2, M. Dubinsky2, B. Abhyankar3, A. James3, K. Lasch4

1Academic Medical Centre, Amsterdam, Netherlands, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom, 4Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States

DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

E.V. Loftus Jr1, J.-F. Colombel*2, A. Previtali3, M. Smyth3

1Mayo Clinic, Rochester, Minnesota, United States, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom

DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

W. Sandborn*1, B. Feagan2, G. D’Haens3, B. Levesque4, R. Pai5, S. Hanauer6, D. Wolf7, S. Vermeire8, S. Ghosh9, H. Smith10, M. Cravets10, P. Frohna10, S. Gujrathi10, R. Aranda10, A. Olson10

1University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 2Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Ontario, Canada, 3Academic Medical Centre (AMC), Amsterdam, Netherlands, 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 5Mayo Clinic, Scottsdale, Arizona, United States, 6Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 7Atlanta Gastroenterology Associates, Atlanta, Georgia, United States, 8University of Leuven, Leuven, Belgium, 9University of Calgary, Calgary, Canada, 10Receptos, Inc., San Diego, California, States

DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn’s disease: results of 2 Phase 2b randomised placebo-controlled trialsECCO '16 Amsterdam
Year: 2016
Authors:

J. Panés*1, M. Moscariello2, E. Maller2, G. Chan2, W. Wang2, P. Healey3

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Pfizer Inc, Collegeville, United States, 3Pfizer Inc, Groton, Connecticut, United States

DOP054: Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

J.-F. Colombel*1, M. Keir2, A. Scherl2, R. Zhao2, G. de Hertogh3, W. Faubion4, T. Lu2

1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States, 2Genentech, South San Francisco, California, United States, 3Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium, 4Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States

DOP055: Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohn’s disease: the Multicentre azithromycin for Crohn’s disease AZCRO trialECCO '16 Amsterdam
Year: 2016
Authors:

A. Levine*1, 2, J. Kierkuś3, M. Kori4, M. Sladek5, R. Sigall Boneh1, J. Escher6, E. Wine7, B. Yerushalmi8, J. Amil Dias9, R. Shaul10, A. Akriv11, D. Zucker11, D. Turner11, 12

1Wolfson Medical Centre, Paediatric Gastroenterology and Nutrition Unit, Tel-Aviv, Israel, 2Tel Aviv University, Tel-Aviv, Israel, 3The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 4Kaplan Medical Centre, Paediatric Day Care Unit, Rehovot, Israel, 5Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, 6Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 7University of Alberta, Division of Paediatric Gastroenterology, Department of Paediatrics, Edmonton, Canada, 8Soroka Medical Centre, Ben Gurion University of the Negev, Paediatric Gastroenterology, Beer-Sheva, Israel, 9Hospital, S. João, Department of Paediatrics, Porto, Portugal, 10Meyer Children’s Hospital, Gastroenterology Unit, Haifa, Israel, 11The Hebrew University of Jerusalem, Jerusalem, Israel, 12Shaare Zedek Medical Centre, The Juliet Keidan Institute of Paediatric Gastroenterology & Nutrition, Jerusalem, Israel

DOP056: Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label studyECCO '16 Amsterdam
Year: 2016
Authors:

O. J. Adedokun*1, D. Chan1, L. Padgett1, Y. Xu1, J. Hyams2, D. Turner3, Z. Xu1, H. Davis1, R. Strauss1

1Janssen R & D, LLC, Spring House, Pennsylvania, United States, 2Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 3The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Centre, Jerusalem, Israel

DOP057: Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn’s disease (BELCRO)ECCO '16 Amsterdam
Year: 2016
Authors:

L. Wauters*1, F. Smets2, E. De Greef3, I. Hoffman4, P. Bontems5, S. Van Biervliet6, I. Paquot7, P. Alliet8, W. Arts9, M. De Vos10, P. Bossuyt11, J.-F. Rahier12, O. Dewit13, T. Moreels13, D. Franchimont14, V. Muls14, F. Fontaine15, E. Louis15, J.-C. Coche16, B. Hauser3, H. Peeters17, E. Van de Vijver18, F. Baert19, S. Vermeire1, G. Veereman3

1UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 2UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium, 3UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium, 4UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium, 5HUDERF, Paediatric Gastroenterology, Brussels, Belgium, 6UZ Gent, Paediatric Gastroenterology, Ghent, Belgium, 7CHC Liège, Paediatric Gastroenterology, Liège, Belgium, 8Jessa ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium, 9ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, 10UZ Gent, Gastroenterology, Ghent, Belgium, 11Imelda ziekenhuis, Gastroenterology, Bonheiden, Belgium, 12UCL Mont Godinne, Gastroenterology, Mont Godinne, Belgium, 13UCL St Luc, Gastroenterology, Brussels, Belgium, 14ULB Erasme, Gastroenterology, Brussels, Belgium, 15CHU Liège, Gastroenterology, Liège, Belgium, 16St Pierre, Gastroenterology, Ottignies, Belgium, 17ST Lucas, Gastroenterology, Ghent, Belgium, 18UZ Antwerpen, Paediatric Gastroenterology, Antwerp, Belgium, 19Heilig Hart Ziekenhuis, Gastroenterology, Roeselaere, Belgium

DOP058: Long-term avoidance of steroids associated with exclusive enteral nutrition as induction therapy in paediatric Crohn’s disease does not increase surgery, hospitalisations or biologics use: results of a propensity score-matched cohort analysisECCO '16 Amsterdam
Year: 2016
Authors:

S. Basseri1, J. Connors2, A. Grant2, B. MacIntyre2, N. Giffin1, G. Mahdi2, A. Noble2, M. Rashid2, A. R. Otley2, J. Van Limbergen*2

1Dalhousie University, Halifax, Canada, 2IWK Health Centre, Halifax, Canada

DOP059: Efficacy of exclusive enteral nutrition in adult active Crohn’s disease with complications or failure of medical treatmentECCO '16 Amsterdam
Year: 2016
Authors:

Q. Yang, X. Gao*, M. Zhi, H. Chen, N. Ding, S. Hu, J. Guo, P. Hu

The Sixth Affiliated Hosptial, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China

DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared with ADA exposureECCO '16 Amsterdam
Year: 2016
Authors:

S. Kanis*1, A. de Lima1, C. van der Ent2, C. van der Woude1

1Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2Erasmus Medical Centre, Rotterdam, Netherlands

DOP061: Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

S. Kanis*, A. de Lima, C. van der Woude

Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands

DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

L. de Ridder1, M. Joosse*2, D. Turner3, D. Wilson4, S. Koletzko5, J. Martin-de-Carpi6, U. Fagerberg7, C. Spray8, M. Sladek9, R. Shaoul10, E. Roma-Giannikou11, J. Bronsky12, D. Serban13, S. Cucchiara14, G. Veres15, F. Ruemmele16, I. Hojsak17, K. Kolho18, I. Davies19, M. Aloi20, P. Lionetti21, G. Veereman-Wauters22, C. Braegger23, E. Trindade24, A. V. Wewer25, A. Hauer26, A. Levine27

1Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 2Erasmus MC, Laboratory of Paediatrics, division Gastroenterology and Nutrition, Rotterdam, Netherlands, 3Shaare Zedek Medical Centre in Jerusalem, Department of Paediatric Gastroenterology, Jerusalem, Israel, 4University of Edinburgh, Department of Paediatric Gastroenterology, Child Life and Health, Edinburgh, United Kingdom, 5University of Munich Medical Centre, Dr. v. Hauner Children’s Hospital, Department of Paediatric Gastroenterology, Munich, Germany, 6Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Paediatrica, Hospital Sant Joan de Déu, Department of Paediatric Gastroenterology, Barcelona, Spain, 7Centre for Clinical Research, Västmanland Hospital, Västerås, Department of Paediatric Gastroenterology, Stockholm, Sweden, 8Bristol Royal Hospital for Children, Department of Paediatric Gastroenterology, Bristol, United Kingdom, 9Polish-American Children’s Hospital, Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, 10Bnai Zion Medical Centre, Paediatric Day Care Unit, Department of Paediatrics, Haifa, Israel, 11Athens University, First Department of Paediatrics, Athens, Greece, 12Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Paediatric Gastroenterology, Prague, Czech Republic, 13“Iuliu Hatieganu” University of Medicine and Pharmacy, Second Paediatric Clinic, Children’s Emergency Hospital, Department of Paediatric Gastroenterology, Cluj-Napoca, Romania, 14”La Sapienza” University, Department of Paediatric Gastroenterology, Rome, Italy, 15Semmelweis University, Department of Paediatric Gastroenterology, Budapest, Hungary, 16Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, 17Referral Centre for Paediatric Gastroenterology, Children’s Hospital Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Croatia, 18Children’s Hospital, University Central Hospital and University of Helsinki, Department of Paediatric Gastroenterology, Helsinki, Finland, 19University Hospital of Wales, Department of Paediatric Gastroenterology, Cardiff, United Kingdom, 20Sapienza University of Rome, Department of Paediatric Gastroenterology, Rome, Italy, 21Meyer Children’s Hospital, Department of Paediatric Gastroenterology, Florence, Italy, 22University Hospital Brussels, UZBrussels, Department of Paediatric Gastroenterology and Nutrition, Brussels, Belgium, 23Children’s Research Centre, University Children’s Hospital, Department of Paediatric Gastroenterology and Nutrition, Zürich, Switzerland, 24Hospital São João, Paediatric Gastroenterology Unit, Porto, Portugal, 25University Hospital Hvidovre, Department of Paediatrics, Hvidovre, Denmark, 26Medical University of Graz, Paediatric Gastroenterology, Graz, Austria, 27The Wolfson Medical Centre, Tel-Aviv University, Department of Paediatric Gastroenterology, Tel-Aviv, Israel

DOP063: Measurement of endoscopic severity in a Crohn’s disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohn’s Disease Activity Index (PCDAI)ECCO '16 Amsterdam
Year: 2016
Authors:

N. Carman*1, P. Church1, H. Huynh2, D. Mack3, K. Jacobson4, A. Otley5, J. De Bruyn6, W. El-Matery7, C. Deslandres8, M. Carroll2, E. Wine2, E. Benchimol3, J. Van Limbergen5, A. Griffiths1, T. Walters1

1The Hospital for Sick Children, Toronto, Canada, 2University of Alberta, Edmonton, Canada, 3Children’s Hospital of Eastern Ontario, Ottawa, Canada, 4British Columbia Children’s Hospital, Vancouver, Canada, 5IWK Health Centre, Halifax, Canada, 6Alberta Children’s Hospital, Calgary, Canada, 7University of Manitoba, Winnipeg, Canada, 8Sainte-Justine University Hospital Centre, Montreal, Canada

DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabECCO '16 Amsterdam
Year: 2016
Authors:

B. r*1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, E. Del Tedesco2, S. Paul2, Y. Chowers3, R. Eliakim1, S. Ben-Horin1, X. Roblin2

1Sheba Medical Centre & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, 3Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel